MRI Assessment of Placental Health
Launched by BOSTON CHILDREN'S HOSPITAL · Nov 19, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "MRI Assessment of Placental Health," aims to find better ways to determine the safest time for delivering babies at risk of stillbirth due to a condition called Intrauterine Growth Restriction (IUGR). IUGR can happen when the placenta, which is the organ that supplies oxygen and nutrients to the baby, does not function properly. The researchers will use MRI (a type of imaging that provides detailed pictures of the placenta) to check how well the placenta is working. By studying how well oxygen is being transported in the placenta, they hope to identify which pregnancies are at higher risk and make more informed decisions regarding the timing of delivery.
To participate in this study, pregnant women aged 18 to 45 who are carrying either twins or a single baby and have been diagnosed with IUGR are eligible. This includes cases where one twin is not growing as well as the other or where a single baby is smaller than normal. Participants will undergo MRI scans to assess their placental health, and the information gathered will help researchers understand the relationship between placental function and pregnancy outcomes. It's important to note that mothers with certain medical conditions or those who cannot safely undergo an MRI will not be eligible for this study.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- 1. The pregnant mother with twin gestation with diagnosis of selective IUGR based upon obstetrical US findings as following:
- • Proven monochorionicity / dichorionicity
- • Discordance in estimated fetal weight (EFW). Growth restriction (\<10 percentile of norm) in one or both fetus(es) AND/OR growth discordance (\> or = 20%) between twin fetuses.
- 2. The pregnant mother with singleton gestation with diagnosis of IUGR based upon obstetrical US findings as following:
- • Proven singleton gestation
- • Growth restriction of fetus (\<10 percentile of norm)
- • Doppler measurements that indicates placental insufficiency: umbilical artery, middle cerebral artery, uterine artery; or oligohydramnios.
- • 3. Gestational age: Bigger than 18 weeks.
- • 4. Pregnant mother is between age 18 to 45, clinically stable and can safely tolerate fetal MRI study.
- Exclusion Criteria:
- • Fetuses/infants with the following features will be excluded.
- • 1. Fetus/infant with chromosomal anomalies or known genetic disorders.
- • 2. Fetus/infant with other major congenital malformation.
- • 3. Presence of any condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient, quality or completeness of the data.
- • Pregnant mothers with the following features will be excluded.
- • 1. Mothers with contraindication to MRI (with pacemaker, metal in body, oversize).
- • 2. Mothers with claustrophobia
- • 3. Mothers medically unstable for the MRI study
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Madrid, , Spain
Patients applied
Trial Officials
Patricia E Grant, MD
Principal Investigator
Boston Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials